Showing results (131-140 of 143) with videos related to
Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancerSetsuko K Chambers, Mary C Clouser, Amanda F Baker, et al.Cancer Prevention Research (Philadelphia, Pa.)|February 14, 2018
Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 MiceKaren Blohm-Mangone, Nichole B Burkett, Shekha Tahsin, et al.Scientific Reports|February 5, 2024
Cell-free DNA methylation analysis as a marker of malignancy in pleural fluidBillie Bixby, Lukas Vrba, Jyoti Lenka, et al.JNCI Cancer Spectrum|January 23, 2025
Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidenceJennifer W Bea, Heather M Ochs-Balcom, Celina I Valencia, et al.Journal of the National Cancer Institute|August 18, 2016
Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled TrialPatricia A Thompson, Erin L Ashbeck, Denise J Roe, et al.Journal of the National Cancer Institute|August 18, 2016
Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 DiabetesPatricia A Thompson, Erin L Ashbeck, Denise J Roe, et al.Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2012
Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma preventionPatricia Thompson, Denise J Roe, Liane Fales, et al.Blood|July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaPaul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast CancerMiguel Quintela-Fandino, Begoña Bermejo, Esther Zamora, et al.The Oncologist|June 10, 2026
A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM) and paricalcitol as neoadjuvant therapy in pancreatic cancerAlexa F Viniotis, Gayle S Jameson, Betsy C Wertheim, et al.Pageof 15